From Genes to Mechanisms: The Expanding Spectrum of Monogenic Disorders Associated with Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Volumn 22, Issue 1, 2016, Pages 202-212

  Uhlig, Holm H ^a,b   Schwerd, Tobias ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Crohn's disease; genetics; genome wide association study; IBD unclassified; immunodeficiency; indeterminate colitis; inflammatory bowel disease; next generation sequencing; pediatrics; ulcerative colitis; unclassified colitis; whole exome sequencing

Indexed keywords

ADAPTIVE IMMUNITY; BACTERIAL COLONIZATION; COMMENSAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INFECTION SENSITIVITY; INFLAMMATORY BOWEL DISEASE; INHERITANCE; INNATE IMMUNITY; INTESTINE FLORA; MONOGENIC DISORDER; NONHUMAN; PENETRANCE; PRIORITY JOURNAL; REVIEW; COMPLICATION; GENE; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETICS; INFLAMMATORY BOWEL DISEASES;

GENES; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84964691126     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000614     Document Type: Review

References (95)

1. Van Limbergen J, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroenterol Hepatol. 2014;11:372-385.
2. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
3. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298-306.
4. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Review Immunology. 2010;28:573-621.
5. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713-1725.
6. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
7. Hyams JS. Standardized recording of parameters related to the natural history of inflammatory bowel disease: from Montreal to Paris. Dig Dis. 2014;32:337-344.
8. Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990-1007.e3.
9. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
10. Moran CJ, Klein C, Muise AM, et al. Very early-onset inflammatory bowel disease: gaining insight through focused discovery. Inflamm Bowel Dis. 2015;21:1166-1175.
11. Okou DT, Kugathasan S. Role of genetics in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1878-1884.
12. Fairfax BP, Humburg P, Makino S, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343:1246949.
13. Farh KK, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518:337-343.
14. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut. 2011;60:1739-1753.
15. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10:43-55.
16. Ananthakrishnan AN, Xavier RJ. How does genotype influence disease phenotype in inflammatory bowel disease? Inflamm Bowel Dis. 2013;19: 2021-2030.
17. Lee JC, Espeli M, Anderson CA, et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell. 2013;155:57-69.
18. Schnitzler F, Friedrich M, Wolf C, et al. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067. PLoS One. 2014;9:e108503.
19. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43:1066-1073.
20. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319-1323.
21. Ellinghaus D, Zhang H, Zeissig S, et al. Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology. 2013;145:339-347.
22. Hunt KA, Mistry V, Bockett NA, et al. Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature. 2013;498:232-235.
23. Ananthakrishnan AN, Huang H, Nguyen DD, et al. Differential effect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol. 2014; 109:395-400.
24. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013;62:1795-1805.
25. Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010;38:20-31.
26. Okazaki T, Wang MH, Rawsthorne P, et al. Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a populationbased case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis. 2008;14:1528-1541.
27. Yazdanyar S, Kamstrup PR, Tybjaerg-Hansen A, et al. Penetrance of NOD2/CARD15 genetic variants in the general population. CMAJ. 2010;182:661-665.
28. Silver J. The importance of penetration. Inflamm Bowel Dis. 2003;9:341.
29. Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410-1416.
30. Zeissig S, Petersen BS, Tomczak M, et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut. [published online ahead of print November 3, 2014]. doi: 10.1136/gutjnl-2014-308541.
31. Kuehn HS, Ouyang W, Lo B, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345:1623-1627.
32. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600-603.
33. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192: 295-302.
34. Lord JD, Hackman RC, Moklebust A, et al. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci. 2010;55:1396-1405.
35. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11:852-863.
36. Milner JD, Vogel TP, Forbes L, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood. 2015;125:591-599.
37. Slowik VA Novel variant in the STAT3 gene associated with autoimmune enteropathy in a Father-Son Duo. J Genomes Exomes. 2014;3:1-5.
38. Haapaniemi EM, Kaustio M, Rajala HL, et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood. 2015;125: 639-648.
39. Romberg N, Al Moussawi K, Nelson-Williams C, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46:1135-1139.
40. Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46:1140-1146.
41. Kitamura A, Sasaki Y, Abe T, et al. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med. 2014;211: 2385-2396.
42. Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature. 2011;477: 596-600.
43. Carvalho FA, Nalbantoglu I, Aitken JD, et al. Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunol. 2012;5:288-298.
44. Naviglio S, Arrigo S, Martelossi S, et al. Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling. J Crohns Colitis. 2014;8:770-774.
45. Frischmeyer-Guerrerio PA, Guerrerio AL, Oswald G, et al. TGFbeta receptor mutations impose a strong predisposition for human allergic disease. Sci Transl Med. 2013;5:195ra194.
46. Gallo EM, Loch DC, Habashi JP, et al. Angiotensin II-dependent TGFbeta signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014;124:448-460.
47. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171-181.
48. Marafini I, Zorzi F, Codazza S, et al. TGF-Beta signaling manipulation as potential therapy for IBD. Curr Drug Targets. 2013;14:1400-1404.
49. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015;372:1104-1113.
50. Ghosh S, Honscheid A, Schwarz K, et al. RAG1 deficiency with a shifting B cell phenotype and chromosomal instability. Clin Immunol. 2014;152:65-67.
51. Schaballie H, Rodriguez R, Martin E, et al. A novel hypomorphic mutation in STIM1 results in a late-onset immunodeficiency. J Allergy Clin Immunol. 2015;136:816-819.e4.
52. Lowe D, Verma N, Dziadzio M, et al. Clinical and immunological heterogeneity in a family with the E1021K activating mutation in phosphoinositide 3-kinase delta. ESID abstract.
53. Lowe D. Clinical and immunological heterogeneity in a family with the E1021K activating mutation in Phosphoinositide 3-Kinase Delta. 2014.
54. Heindl M, Handel N, Ngeow J, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal b-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology. 2012;142:1093-1096 e1096.
55. Patel N, El Mouzan MI, Al-Mayouf SM, et al. Study of Mendelian forms of Crohn's disease in Saudi Arabia reveals novel risk loci and alleles. Gut. 2014;63:1831-1832.
56. Cardinale CJ, Kelsen JR, Baldassano RN, et al. Impact of exome sequencing in inflammatory bowel disease. World J Gastroenterol. 2013;19: 6721-6729.
57. Egritas O, Dalgic B. Infantile colitis as a novel presentation of familial Mediterranean fever responding to colchicine therapy. J Pediatr Gastroenterol Nutr. 2011;53:102-105.
58. Lanternier F, Mahdaviani SA, Barbati E, et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida speciesinduced meningoencephalitis, colitis, or both. J Allergy Clin Immunol. 2015;135:1558-1568 e1552.
59. Hong SN, Park C, Park SJ, et al. Deep resequencing of 131 Crohn's disease associated genes in pooled DNA confirmed three reported variants and identified eight novel variants. Gut. [published online ahead of print March 2, 2015]. doi: 10.1136/gutjnl-2014-308617.
60. Dobbs K, Dominguez Conde C, Zhang SY, et al. Inherited DOCK2 deficiency in patients with early-onset invasive infections. N Engl J Med. 2015;372:2409-2422.
61. Kammermeier J, Drury S, James CT, et al. Targeted gene panel sequencing in children with very early onset inflammatory bowel disease-evaluation and prospective analysis. J Med Genet. 2014;51:748-755.
62. Gerada J, DeGaetano J, Sebire NJ, et al. Mucosal inflammation as a component of tufting enteropathy. Immunogastroenterology. 2013;2:62-67.
63. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
64. Spencer SD, Di Marco F, Hooley J, et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J ExpMed. 1998;187:571-578.
65. Zigmond E, Bernshtein B, Friedlander G, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity. 2014;40:720-733.
66. Shouval DS, Biswas A, Goettel JA, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and antiinflammatory macrophage function. Immunity. 2014;40:706-719.
67. Uhlig HH, Coombes J, Mottet C, et al. Characterization of Foxp3 +CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol. 2006;177:5852-5860.
68. Glocker EO, Frede N, Perro M, et al. Infant colitis-it's in the genes. Lancet. 2010;376:1272.
69. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361: 2033-2045.
70. Engelhardt KR, Grimbacher B. IL-10 in humans: lessons from the gut, IL-10/IL-10 receptor deficiencies, and IL-10 polymorphisms. Curr Top Microbiol Immunol. 2014;380:1-18.
71. van der Linde K, Boor PP, van Bodegraven AA, et al. A functional interleukin-10 mutation in Dutch patients with Crohn's disease. Dig Liver Dis. 2005;37:330-335.
72. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170-181.
73. Dhillon SS, Fattouh R, Elkadri A, et al. Variants in NADPH oxidase complex components Determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology. 2014;147:680-689.e2.
74. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014; 508:469-476.
75. Casanova JL, Conley ME, Seligman SJ, et al. Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. J Exp Med. 2014;211:2137-2149.
76. Ammann S, Elling R, Gyrd-Hansen M, et al. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin Exp Immunol. 2014;176:394-400.
77. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143:347-355.
78. Sanal O, Jing H, Ozgur T, et al. Additional diverse findings expand the clinical presentation of DOCK8 deficiency. J Clin Immunol. 2012;32: 698-708.
79. Engelhardt KR, Gertz ME, Keles S, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015;136:402-412.
80. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98: 1010-1020.
81. Farmer MA, Sundberg JP, Bristol IJ, et al. A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A. 2001;98:13820-13825.
82. Beckwith J, Cong Y, Sundberg JP, et al. Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens. Gastroenterology. 2005;129:1473-1484.
83. Alcais A, Abel L, Casanova JL. Human genetics of infectious diseases: between proof of principle and paradigm. J Clin Invest. 2009;119:2506-2514.
84. Casanova JL, Abel L. The genetic theory of infectious diseases: A brief history and selected illustrations. Annu Rev Genomics Hum Genet. 2013; 14:215-243.
85. Abel L, El-Baghdadi J, Bousfiha AA, et al. Human genetics of tuberculosis: A long and winding road. Philos Trans R Soc Lond B Biol Sci. 2014; 369:20130428.
86. Chiodini RJ, Chamberlin WM, Sarosiek J, et al. Crohn's disease and the mycobacterioses: A quarter century later. Causation or simple association? Crit Rev Microbiol. 2012;38:52-93.
87. Liverani E, Scaioli E, Cardamone C, et al. Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon? World J Gastroenterol. 2014;20:13060-13070.
88. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med. 2009;361:2609-2618.
89. Zhang F, Liu H, Chen S, et al. Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat Genet. 2011; 43:1247-1251.
90. Cao Y, Shen J, Ran ZH. Association between faecalibacterium prausnitzii reduction and inflammatory bowel disease: A meta-analysis and Systematic review of the Literature. Gastroenterol Res Pract. 2014; 2014:872725.
91. Ghouri YA, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473-487.
92. Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest. 2014:1-7.
93. Mukhopadhya I, Hansen R, Meharg C, et al. The fungal microbiota of denovo paediatric inflammatory bowel disease. Microbes Infect. 2015;17: 304-310.
94. Norman JM, Handley SA, Baldridge MT, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015;160: 447-460.
95. Nguyen DD, Muthupalani S, Goettel JA, et al. Colitis and colon cancer in WASP-deficient mice require helicobacter species. Inflamm Bowel Dis. 2013;19:2041-2050.